Xvivo Perfusion AB (publ) (STO:XVIVO)
279.40
-0.40 (-0.14%)
Apr 17, 2025, 12:59 PM CET
Xvivo Perfusion AB Revenue
In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M SEK with 37.63% growth. Xvivo Perfusion AB had revenue of 227.56M in the quarter ending December 31, 2024, with 46.12% growth.
Revenue
822.42M
Revenue Growth
+37.63%
P/S Ratio
10.70
Revenue / Employee
4.33M
Employees
190
Market Cap
8.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Swedish Orphan Biovitrum AB | 26.03B |
Sectra AB | 3.30B |
Getinge AB | 34.76B |
Camurus AB | 1.87B |
Medicover AB | 23.97B |
Vitrolife AB | 3.61B |
Bonesupport Holding AB | 898.73M |
Vimian Group AB | 4.29B |